MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Veru EBITDA 2011-2026 | VERU
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Veru
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.6 M | -93.5 M | -37.3 M | 13.1 M | -184 K | -5.96 M | -20.4 M | -7.08 M | 4.92 M | 7.11 M | 4.51 M | 10.3 M | 11.4 M | 3.76 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.1 M | -93.5 M | -10.4 M |
Quarterly EBITDA Veru
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.4 M | - | -7.52 M | -8.09 M | -10.2 M | - | -10.5 M | -8.86 M | -7.32 M | - | -13.7 M | -34.4 M | -37.4 M | -38.5 M | -21.8 M | -11.7 M | -4.94 M | 14.9 M | -2.85 M | -1.45 M | 19.2 M | -3.24 M | -1.31 M | 19.2 M | -1.71 M | -4.75 M | -1.77 M | -1.71 M | -969 K | -16.9 M | -4.9 M | -934 K | -7.39 M | -5.45 M | -1.09 M | -7.39 M | -1.79 M | 3.64 M | 1.08 M | -1.79 M | 2.51 M | 6.23 M | 1.71 M | 2.51 M | 1.58 M | 4.84 M | 2.31 M | 1.58 M | 1.73 M | 8.47 M | 1.36 M | 1.73 M | 3.73 M | 8.1 M | 3.03 M | 3.73 M | 2.9 M | 1.34 M | 684 K | 2.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 19.2 M | -38.5 M | -2.92 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Drug manufacturers industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-23.6 M | - | 0.86 % | $ 117 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Assertio Holdings
ASRT
|
8.47 M | $ 18.02 | -2.12 % | $ 115 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-40 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
-260 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
Alimera Sciences
ALIM
|
6.82 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-65.5 M | - | -23.39 % | $ 1.76 M | USA |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-39.7 M | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
3.06 M | $ 3.11 | -0.96 % | $ 43.7 M | USA |
 |
Cronos Group
CRON
|
-176 M | $ 2.55 | 0.79 % | $ 1.33 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
2.23 B | $ 5.39 | 0.75 % | $ 1.97 B | Canada |
 |
Harrow Health
HROW
|
31.8 M | $ 37.29 | 1.52 % | $ 1.37 B | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.48 | 1.46 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-95.6 M | $ 1.09 | 4.81 % | $ 117 M | Canada |
 |
Jupiter Wellness
JUPW
|
654 K | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
-142 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
-25.2 M | $ 4.24 | 3.67 % | $ 273 M | USA |
 |
Emergent BioSolutions
EBS
|
-601 M | $ 8.45 | 0.72 % | $ 433 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-100 M | - | - | $ 193 M | Canada |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.44 | 3.6 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
12.3 M | $ 2.29 | -4.18 % | $ 302 M | USA |
 |
Pacira BioSciences
PCRX
|
5.41 M | $ 23.82 | 2.45 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
81.6 M | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.38 | 1.47 % | $ 3.37 M | Canada |
 |
ProPhase Labs
PRPH
|
28.3 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-53.2 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
4.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 7.61 | 8.56 % | $ 300 M | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.99 | -0.4 % | $ 49.4 M | USA |
 |
OptiNose
OPTN
|
-22.3 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-40.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-178 M | $ 8.1 | 1.0 % | $ 709 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 6.72 | -0.44 % | $ 4.15 B | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.57 M | $ 2.41 | 5.24 % | $ 2.99 M | USA |
 |
Viatris
VTRS
|
3.51 B | $ 13.61 | 0.29 % | $ 16.3 B | USA |
 |
cbdMD
YCBD
|
-2.86 M | $ 0.65 | -6.59 % | $ 2.8 M | USA |
 |
Zomedica Corp.
ZOM
|
-82.3 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-2.5 M | $ 0.93 | -0.98 % | $ 33.5 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-1.74 M | $ 0.66 | 5.66 % | $ 2.83 M |  China |
 |
TherapeuticsMD
TXMD
|
-4.01 M | $ 2.05 | - | $ 23.7 M | USA |